0

Home > Drug Category > Cancer Medications > Jakafi and Equivalent

Jakafi (Ruxolitinib phosphate) Information

Jakafi, which contains the active ingredient ruxolitinib, is an oral targeted therapy known as a JAK (Janus Kinase) inhibitor. It is specifically indicated for the treatment of patients with intermediate or high-risk myelofibrosis, a severe bone marrow disorder. It is also used to manage polycythemia vera in individuals who have had an inadequate response to hydroxyurea, and for treating both acute and chronic graft-versus-host disease (GvHD). By specifically targeting the cellular pathways responsible for these conditions, Jakafi helps shrink an enlarged spleen and alleviate debilitating systemic symptoms such as severe itching, night sweats, and bone pain. It is usually taken as a tablet twice per day.

The mechanism of action involves the inhibition of the JAK1 and JAK2 enzymes. These kinases are part of a signaling pathway that regulates the production of blood cells and the body's inflammatory response. Under targeted conditions, this pathway is often overactive or mutated, leading to uncontrolled cell growth and elevated levels of inflammatory cytokines. Jakafi works by "turning down" this signaling, helping stabilize blood cell counts, reduce inflammation, and decrease the physical size of the spleen.

Jakafi Side Effects

Jakafi is generally well-tolerated, but some common side effects may occur as your body adjusts to the medication. Commonly reported effects include dizziness, headache, fatigue, and an increased tendency to bruise. Many patients also experience laboratory changes, such as a drop in red blood cells (anemia) or platelets (thrombocytopenia). Some individuals may also experience weight gain or an increase in cholesterol levels.

More serious side effects can occur and require immediate medical attention. Stop taking the medication and seek help if you experience:
• Cardiovascular Issues: Sudden shortness of breath, chest pain, or swelling in the legs, which may indicate a blood clot or heart-related complication.
• Hepatitis B Reactivation: If you have had Hepatitis B in the past, it may become active again; watch for yellowing of the skin or eyes and upper stomach pain.
• Severe Bleeding: Unusual or heavy bleeding, blood in your urine or stool, or bruising that appears without cause.
• Severe Infections: Signs such as fever, chills, or a painful, blistering skin rash (shingles), as the drug can lower your ability to fight germs.
• Skin Lesions: New growths on the skin or changes in existing moles, as there is an increased risk of certain non-melanoma skin cancers.

Jakafi Precautions

Do not use Jakafi if you have a known allergy to ruxolitinib or any of the inactive ingredients in the tablet. Before starting treatment, inform your doctor of your complete medical history, especially if you have ever had tuberculosis, chronic infections like shingles or Hepatitis B, kidney or liver disease, or high cholesterol. You should also mention if you have a history of smoking or heart problems, as these factors may increase your risk of developing severe blood clots or major cardiovascular events during treatment.

Tell your doctor about all medications you take, as several drugs can interfere with how Jakafi is cleared from your system. Strong CYP3A4 inhibitors, such as antifungals like ketoconazole or antibiotics like clarithromycin, can significantly increase Jakafi levels, often requiring a dose adjustment. It is also essential to avoid consuming grapefruit or grapefruit juice, as these can interact with the medication and increase the risk of side effects. Ensure your doctor is aware of any other supplements or blood-thinning medications you are currently using.

Inform your doctor if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. Jakafi is not recommended for use during pregnancy unless the potential benefit clearly outweighs the risks to the developing fetus. Women should not breastfeed while taking Jakafi and should wait at least two weeks after the final dose before resuming, as it is unknown if the medication passes into breast milk and poses a risk to the infant.

Take Jakafi exactly as prescribed by your oncologist. It is vital that you do not stop taking this medication abruptly, as a sudden discontinuation can lead to a "withdrawal syndrome" where myelofibrosis symptoms return quickly and severely. Contact your doctor immediately; do not stop treatment unless directed. If a dose is missed, skip it entirely and take your next dose at the regular time. Store the medication at room temperature in a dry place, and keep the bottle tightly closed.

Do I need a prescription to order Jakafi?

Yes, a prescription is required from your physician to order Jakafi.